PT-141

PT-141 (Bremelanotide) 10mg by Dragon Pharma

PT-141 (Bremelanotide) is Dragon Pharma's formulation of the FDA-approved melanocortin receptor agonist at 10mg per vial — the only libido-enhancing peptide with regulatory approval for sexual dysfunction. PT-141 is a metabolite of Melanotan II with more selective MC4R activity, acting centrally through the nervous system to enhance sexual arousal and desire through a mechanism entirely distinct from PDE5 inhibitors (Viagra, Cialis). FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women, it is widely used for both sexes in performance and sexual health contexts.

Also searched as: PT-141, Bremelanotide 10mg, PT141 libido peptide, Vyleesi, PT-141 Dragon Pharma.

PT-141's Origin — The Melanotan II Connection

PT-141 has a specific relationship to Melanotan II that most competitor content doesn't explain:

• During research on Melanotan II's tanning effects, researchers observed potent spontaneous erection responses in male test subjects — an unexpected finding attributed to Melanotan II's activation of MC4R in the CNS
• PT-141 was specifically developed to isolate and enhance this MC4R sexual effect while reducing the MC1R tanning effect of Melanotan II. PT-141 is a cyclised hexapeptide derived from Melanotan II with modified structure for more selective MC4R activity and less MC1R activity
• Unlike Melanotan II's broad multi-receptor profile (MC1R, MC3R, MC4R, MC5R), PT-141 has greater relative selectivity for MC4R — explaining why PT-141 produces more targeted sexual response with less tanning versus the full Melanotan II profile
• PT-141's ~2.7 hour half-life is shorter than Melanotan II's — it is designed for acute on-demand dosing rather than the sustained tanning protocol of Melanotan II

Central vs Peripheral — Why PT-141 Is Different From PDE5 Inhibitors

This is the most important mechanistic distinction and the most consistently omitted from competitor content:

• PDE5 inhibitors (Sildenafil/Viagra, Tadalafil/Cialis) act peripherally — they block the enzyme that breaks down cGMP in penile smooth muscle, allowing sustained vasodilation and facilitating erection. They require sexual stimulation to work and do not address the central (brain-level) sexual desire component
• PT-141 acts centrally — it activates MC4R in the hypothalamus and other brain regions that regulate sexual motivation, arousal and desire. It works at the level where the "drive" for sexual activity originates, not at the peripheral mechanics of achieving erection
• The practical consequence: PT-141 can produce sexual desire and arousal in the absence of direct physical stimulation — it can restore or enhance sexual motivation that PDE5 inhibitors cannot address. It also works in women for this reason (PDE5 inhibitors have minimal efficacy in women)
• For psychogenic erectile dysfunction (where the cause is psychological/central rather than vascular/peripheral), PT-141 addresses the actual source while PDE5 inhibitors only manage the peripheral consequence

PT-141 vs Melanotan II vs PDE5 Inhibitors

The FDA Approval — What Vyleesi Means

PT-141 received FDA approval in 2019 as Vyleesi (palatin Technologies / AMAG Pharmaceuticals) for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women — a specific and significant regulatory milestone:

• HSDD is defined as persistently or recurrently deficient or absent sexual desire that causes significant distress. The approval validated PT-141's central MC4R mechanism as clinically meaningful for sexual function
• The approval was specifically for premenopausal women — not for men, though the mechanism applies equally. Male sexual dysfunction trials have been conducted but male HSDD is not a formally recognised FDA indication
• The approved clinical dose is 1.75mg subcutaneously 45 minutes before anticipated sexual activity — the performance context dose of 1-2mg is consistent with the clinical dose
• The FDA label includes blood pressure monitoring as a precaution — PT-141 can cause transient blood pressure increases of approximately 6mmHg systolic

Effects and Benefits

• Enhanced sexual desire and arousal through central MC4R activation — the primary and FDA-confirmed effect
• Spontaneous erections in men — direct CNS sexual arousal without requiring physical stimulation
• Effective for psychogenic sexual dysfunction where PDE5 inhibitors provide no benefit
• Works in women — the only pharmacologically validated libido compound with female-specific clinical trial data and approval
• Minimal tanning effect compared to full Melanotan II
• No hormonal suppression — no PCT required

Dosage and Administration

At 10mg per vial, the 1.75mg clinical dose provides approximately 5-6 uses per vial. The ~2.7-hour half-life means effects peak within 1-2 hours and last 4-6 hours. Reconstitute with bacteriostatic water. Inject subcutaneously — abdomen or thigh. Store reconstituted vial refrigerated at 2-8°C for up to 28 days.